DOCSTOR: 1471841\4
FOR IMMEDIATE RELEASE
PHARMENG RELOCATES PERTH, ONTARIO PHARMACEUTICAL
CONTRACT MANUFACTURING OPERATIONS TO NEW FACILITY IN
SYDNEY, NOVA SCOTIA
Toronto, Canada, June 17, 2008 – PharmEng International Inc.
("PharmEng") (TSX VENTURE:PII),today announced that its wholly owned subsidiary, Keata Pharma Inc., is relocating contract manufacturing operations from the Perth, Ontario (“Perth”) facility to their state-of-the-art pharmaceutical manufacturing facility in Sydney, Nova Scotia. Included in the relocation from Perth are existing pharmaceutical supply contracts, manufacturing equipment and personnel.

The 46,400 sq. ft. Sydney facility includes offices for PharmEng’s pharmaceutical consulting division, pilot laboratories for formulation development, production rooms with various capabilities such as high shear mixing, container blending and equipment for modified release technologies.

The facility provides formulation development and testing
services to manufacture and package products in solid and liquid dosage forms. The Sydney facility has been designed to meet all cGMP requirements. Keata's long-term goal is to develop capabilities in other dosage forms, such as suppositories, topicals and injectables. The facility is located on five acres in the Northside Industrial Park, a 300 acre business park in North Sydney, NS.

The transition from the Perth facility to the Sydney facility was
completed on May 30, 2008.

Stock Option Grants
At a meeting June 4, 2008 the Board approved and granted 320,000 options to two members of the senior management team under the Company Stock Option Plan at a strike price of $0.45 vesting over three years.

About PharmEng International Inc.
PharmEng International Inc., headquartered in Toronto, Canada, is a full-service consulting and contract manufacturing company that serves the pharmaceutical and biotechnology industries in North America and internationally. Consulting services include project management, engineering, GMP, validation, calibration, regulatory compliance and ertified training. Contract manufacturing includes pharmaceutical support, formulation development, laboratory testing, and finished solid dosage and liquid products. PharmEng’s shares trade on the TSX Venture Exchange under the symbol PII. For more information about PharmEng International Inc. (TSX-V: PII), visit the Company’s website at www.pharmeng.com.

FORWARD LOOKING STATEMENTS
Certain statements in this press release may include “forward-looking” statements which involve known and unknown
risks, uncertainties and other factors which may cause actual results, performance or achievements of PharmEng to be
materially different from any future results, performance or achievements expressed or implied by such forward-looking
statements. When used in this press release, such statements use such words as “may”, “will”, “expect”, “anticipate”,
“project”, “believe”, “plan”, and other similar terminology. The risks and uncertainties are detailed from time to time in
reports filed by PharmEng with the securities regulatory authorities in all of the provinces and territories of Canada. New
risk factors may arise from time to time and it is not possible for management to predict all of those risk factors or the
extent to which any factor or combination of factors may cause actual results, performance and achievements of
PharmEng to be materially different from those contained in forward-looking statements. Given these risks and
uncertainties, investors should not place undue reliance on forward-looking statements as a prediction actual results.
For further information please contact:
PharmEng International Inc.
Bert Loveless, CFO
Chief Financial Officer
Tel: (905) 415 3922 x 107
E-mail: [email protected]